<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867358</url>
  </required_header>
  <id_info>
    <org_study_id>KT07-US-01</org_study_id>
    <nct_id>NCT02867358</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of KT07 Capsule in the U.S.A</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, and Placebo-controlled Phase II Clinical Study to Investigate the Safety and Efficacy of Two Doses of KT07 Compared to Placebo in Subjects With Acute Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yiling Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yiling Pharmaceutical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation
      of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains,
      fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the improvement in reducing the duration of illness compared to placebo.</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Duration of illness is defined as: the length of time to alleviation of all symptoms.
The duration of alleviation is calculated from time 0 (first administration of study medication) to the time at which symptom is alleviated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The reduction in duration of alleviation of individual symptom</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>From time zero to the time at which the symptom is less than or equal to mild and stable for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Based on the self-assessment questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of viral shedding</measure>
    <time_frame>At day 3 and day 6</time_frame>
    <description>Use RT-PCR and TCID50 assay to quantitate virus load</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>High dose of KT07 capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose of KT07 capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KT07 Capsule</intervention_name>
    <arm_group_label>High dose of KT07 capsule</arm_group_label>
    <arm_group_label>Low dose of KT07 capsule</arm_group_label>
    <other_name>Lianhua Qingwen Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Low dose of KT07 capsule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with mild or moderate acute uncomplicated influenza with oral temperature of
             37.3-39.3℃ (99.1-102.8°F); plus at least one respiratory symptom (nasal congestion,
             sore throat or cough); and at least one constitutional symptoms (aches and pains,
             fatigue, headache and chills or sweats).

          2. Subjects with Rapid Influenza Diagnostic Test (RIDT) confirmed influenza infection.

          3. Onset of symptoms less than 48 hours before Visit 1 (Screening; study drug
             administration visit) and receiving no antiviral/anti-influenza medication.

          4. Age 18 to 65 years old.

          5. Subjects who are able to understand and are willing to sign the informed consent form
             (ICF).

          6. All female subjects of child-bearing potential must have a negative urine pregnancy
             test result. All female subjects of child-bearing potential and male subjects and
             their spouse/partner must agree to use a medically acceptable method of contraception
             (e.g., abstinence, an intrauterine device, a double-barrier method such as condom +
             spermicide or condom + diaphragm with spermicide, a contraceptive implant, an oral
             contraceptive or have a vasectomised partner with confirmed azoospermia) throughout
             the entire study period and for 30 days for female and 90 days for male subjects after
             study drug discontinuation.

        Exclusion Criteria:

          1. Subjects who suffer from severe influenza with oral temperature of more than 39.3℃
             (102.8°F) with or without other symptoms.

          2. Subjects who have any of the following documented conditions: Subjects with
             hypertension and diabetes; lower respiratory tract infection other than influenza,
             asthma requiring daily therapy, including acute flare of chronic asthma, bronchial
             asthma, chronic obstructive pulmonary disease (COPD), acute infectious disease, any
             other chronic respiratory disease, bacterial infection of respiratory system, such as:
             suppurative tonsillitis, acute tracheobronchitis, sinusitis, otitis; subjects with
             history of moderate to severe cardiac, hepatic, renal and hematopoietic disorders,
             bleeding tendency or hemorrhagic disease, mental and neurological system disease;
             subjects with hyperthyroidism and increased intraocular pressure; and subjects with
             current cancer.

          3. Subjects with anatomical nasal obstruction or gross anatomical abnormalities. For
             example, nasal polyps or significant nasal septal deviation.

          4. Subjects who have to take other medications for the treatment of influenza or related
             symptoms, including but not limited to antipyretic and analgesic medicines (within 8
             hours prior to randomization), antibiotics, and antiviral drugs.

          5. Subjects with acute dyspnea, wheezing, or moist rales on screening examination.

          6. Clinically very excessively obese subjects with BMI ≥40.

          7. Subjects with recent history (within 1 year) of alcoholism or substance abuse.

          8. Received influenza vaccine within 21 days.

          9. Participation in other clinical trial within 1 month, or during the study.

         10. Pregnant or breast-feeding female subjects.

         11. Allergy or known allergy to components of study medication.

         12. Allergy to aspirin or non-steroid anti-inflammatory drugs (NSAIDs), such as ibuprofen.

         13. Subjects who took a monoamine oxidase inhibitor (MAOI) within 2 weeks prior to
             enrollment.

         14. Subjects received antipyretic and/or analgesic medications for conditions other than
             influenza such as back pain within 8 hours prior to randomization.

         15. Administration of immunomodulators, interferon inducers, homeopathic, hormonal other
             than hormone replacement therapy, antiviral and antibacterial drugs during last 4
             weeks before the first dose.

         16. Previous history of difficulty swallowing capsules.

         17. Any other associated disease or condition which, in the opinion of the investigator,
             might restrict or impede participation in the study or affect the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuedong Gao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yiling Pharmaceutical Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nan Zhang, PhD</last_name>
    <phone>614-441-7888</phone>
    <email>zhangnan@yilingus.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hope Clinical Research, Inc.</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Core Health Care Group</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco L. Badar III, MD</last_name>
      <phone>562-924-8880</phone>
      <email>fbadarmdinc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lalla-Reddy Medical Corp.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Downtown L.A. Research Center, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salil U. Nadkarni, DO</last_name>
      <phone>213-261-3680</phone>
      <email>snadkarni@dtlaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMD Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Facey Medical Foundation</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Center</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Sweet Hope Research Specialty, Inc</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Reyna, MD</last_name>
      <phone>305-456-9062</phone>
      <email>j.reyna@sweethoperesearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finlay Medical Research Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilia Rodriguez Ables, MD</last_name>
      <phone>305-459-3578</phone>
      <email>LRAbles@finlaymedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panamerican Health Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>AppleMed Reseach, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin J. Latorre, MD</last_name>
      <phone>305-667-8434</phone>
      <email>Dr.latorre@applemedresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Nunez-Avila, MD</last_name>
      <phone>305-477-6750</phone>
      <email>Oavilaresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research</name>
      <address>
        <city>Williston</city>
        <state>Florida</state>
        <zip>32696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven A. Geller, MD</last_name>
      <phone>443-698-8678</phone>
      <email>DRG@centennialmedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Detweiler Family Medicine</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Kessler, DO</last_name>
      <phone>215-368-1900</phone>
      <email>afanelli@detweilerfamilymedicine.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad S. Boomershine, MD</last_name>
      <phone>615-577-4017</phone>
      <email>drboomershine@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Hoppers, MD</last_name>
      <phone>731-431-5027</phone>
      <email>drhoppers@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadie Dar, MD</last_name>
      <phone>615-984-3361</phone>
      <email>drdar@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Spring Hill</city>
        <state>Tennessee</state>
        <zip>37174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rennee N. Dhillon, MD</last_name>
      <phone>615-577-4017</phone>
      <email>drdhillon@crssites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Family Physicians</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark C Dawson, MD</last_name>
      <phone>512-892-7076</phone>
      <phone_ext>4126</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates of Texas</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Stewart, MD</last_name>
      <phone>214-379-2272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corpus Christi Family Wellness</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Winnie, MD</last_name>
      <phone>361-288-4668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Village Health Partners</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhavi Ampajwala, MD</last_name>
      <phone>214-379-2272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quaity Assurance Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John R. Cantu, MD</last_name>
      <phone>210-341-2002</phone>
      <email>cantumd@qarcinc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bandera Family Health Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Reyes, MD</last_name>
      <phone>210-296-2445</phone>
      <email>DRREYES@banderafamily.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wade Family Medicine</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc./ Foothill Family Clinic Draper</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen D. Coleman, MD</last_name>
      <phone>385-900-4077</phone>
      <email>scoleman@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Peterson, MD</last_name>
      <phone>801-480-9392</phone>
      <email>jpeterson@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Christensen, MD</last_name>
      <phone>801-480-9392</phone>
      <email>schristensen@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc./ FirstMed East</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Plunkett, MD</last_name>
      <phone>801-480-9392</phone>
      <email>splunkett@jlewisresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CopperView Medical Center</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Banks Turner, MD</last_name>
      <phone>804-477-3045</phone>
      <email>bturnermd@crpllc.info</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute uncomplicated influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

